GENIE Biopharma Collaborative (BPC)

In 2019, AACR GENIE launched the BioPharma Collaborative (BPC), a new research collaboration with a coalition of 9 biopharmaceutical companies. BPC builds on Project GENIE and aims to generate real-world clinico-genomic data by expanding the scope and accelerating the speed of comprehensive clinical data collection for over 130,000 tumor cases that have undergone next generation sequencing using multi-gene panels at the institutions participating in Project GENIE. The focus of the GENIE BPC is to expand the limited clinical data from Project GENIE with detailed phenomic data that characterize baseline patient and tumor attributes, treatment exposures, and cancer outcomes. The phenomic data are curated from electronic health records according to the PRISSMM framework, which utilizes a cancer-agnostic data model that standardizes key components of outcome ascertainment in oncology.

PM-UHN is one of only four institutions to have been selected for participation in phase 1 of GENIE BPC, along with Memorial Sloan Kettering Cancer Center, Dana Farber Cancer Institute, and Vanderbilt Ingram Cancer Center. In 2020, CGP contributed 55 lung cases to GENIE BPC. By the end of 2021, CGP contributed another 70 cases to the pancreas cohort, 60 cases to the prostate cohort, and 47 cases to the bladder cohort.

Datasets from the pancreas, prostate, and bladder cohorts are expected to be released in 2022 and are sure to yield additional projects of scientific impact.